Case studies

Packaging & labeling

Filter by:

Clinical workflows & packaging design

A manufacturer of surgical and delivery devices needed to better understand use cases around the deployment of their crash cart products in typical clinical environments.


The manufacturer wanted to develop new packaging and labeling that would better support clinical teams from a storage and retrieval perspective, as well as a safe and effective use perspective.


We conducted interviews with SMEs from the manufacturer’s organization, as well as contextual inquiries with clinical teams in the field to understand known opportunities for improvement and current challenges.

We used these insights to create a number of simulated use scenarios and conducted lab-based research to refine and prioritize design opportunities.


We provided our client with redesigned packaging and labeling for several products based on what we learned from the clinical workflows associated with crash cart deployments. Many of the design changes significantly mitigated use-related risks.

Surgical mesh implantation procedure

A manufacturer of surgical products had developed a new surgical mesh that provided various advancements in clinical outcomes, but also came with necessary adjustments to implantation procedure.


The manufacturer needed to assess the impacts of these adjustments to surgical teams’ ability to implant the mesh safely and effectively, and tailor the packaging and labeling to clearly communicate the need for the adjustments.


We recruited representative members of surgical teams to conduct simulated implantations in porcine subjects at a simulation lab managed by a local hospital.

Multiple researchers observed the simulated implantations to capture the surgical team dynamics and interactions with the revised implantation procedures.


We provided our client with redesigned packaging and labeling for their surgical mesh product that clearly communicated the necessary procedural adjustments.

With the revised packaging and labeling, residual use-related risks were reduced to acceptable levels.